Federation for Innovative Drug Research Netherlands (FIGON)

FIGON is the integrative platform for innovative drug research in the Netherlands. The Dutch Medicines Days is the conference where partners from Institutes, Industry, and Government can present their findings, share new scientific content and strengthen their network.

Starting on 15 September 2020

Topic: Affordable & Sustainable Drug Development


Dear valued network of the FIGON Dutch Medicines Days,

Due to the Coronavirus (COVID-19), a physical meeting is not possible. The health and safety of our members, speakers and attendees is our number one priority. Even in the midst of COVID-19, the work cannot stop – we must continue to meet, engage, learn and advance. Therefore, this year’s DMD edition will be organised virtually. 

Anke-Hilse Maitland – van der Zee, chairman of the FIGON will officially kick-off the virtual DMD on September 15 . She highlights the background of, and the challenges for, the FIGON. Followed by a keynote lecture by Clémence Ross-van Dorp, ambassador for the Life, Science & Health sector. Afterwards, the Ariëns lecture will be provided by Prof. Rowland.

This years theme is affordable and sustainable drug development. Many new developments are influencing innovation in our field. Big data and artificial intelligence (AI) open new doors in all stages from drug discovery to clinical practice. Other developments, such as options to intervene at the RNA level, quicker ways to screen promising small molecules, and the pressing need for new antibiotics all speed up innovation. These are exciting times in pharmaceutical sciences. Bringing together all bright minds in this field in the Netherlands – established as well as young researchers – the DMD will create momentum for innovation.

We’re confident this year will be no exception and we look forward welcoming you online at the virtual FIGON Dutch Medicines Days 2020.

Soon more information about registration for the virtual DMD 2020!

Subscribe to our mailing list to stay informed about all our virtual meetings later this year. Let’s go virtual together and discuss this year’s theme Affordable & Sustainable Drug Development.

Continuous abstract submission


Please use the abstract template (Download template)


Abstract should be written in English



NVF is proud to participate at the FIGON meeting with a session on Regenerative Pharmacology. This session was featured on the front page of Medicines magazine. The description of the interview with Prof. Amalia Dolga and Prof. Roos Masereeuw can be found here.

Information about the program is found below:

  • Tuesday, September 22nd, 16-17 CET

Prof. Roos Masereeuw,  professor of Experimental Pharmacology at Utrecht University

30 min+ 15 min questions

Title: Bioengineered kidney tubules for regenerative pharmacology

In patients with severe kidney disease, adequate renal clearance is compromised which results in the accumulation of a wide range of endogenous solutes. These uremic retention solutes, also named uremic toxins, are a heterogeneous group of organic compounds with intrinsic biological activities, of which many are too large to be removed by dialysis and/or are protein-bound. Their renal secretion depends largely on active tubular secretion, which shifts the binding and allows for active secretion of the free fraction. To facilitate this process, renal proximal tubule cells are equipped with a range of transporters that cooperate in basolateral uptake and luminal excretion. In recent years, we and others have invested in the development of bioengineered kidneys that could potentially restore this essential function. For this, well-characterized renal tubular epithelial cells were combined with functionalized membranes.

This presentation addresses these developments in the context of renal tubular clearance mechanisms for uremic toxins with emphasis on the role of protein binding, which is compromised in CKD due to posttranslational modifications. This results in increased unbound fractions of uremic toxins accelerating the many complications of CKD. Furthermore, hurdles to take before a safe implementation of bioengineered kidneys in clinics becomes a realistic option will be discussed.

Tuesday, September 29th, 16-17 CET

  • Dr. Wileke Daamen, Principal investigator within the theme Reconstructive & Regenerative Medicine of Radboud university medical center

Title: Biomaterials for soft tissue regeneration

  •  Xinhui Wu, PhD Researcher, University of Groningen

Title: Regenerative Pharmacology for COPD

Please register in advance here.


Tuesday, October 6th, 16-16:45 CET

  • Dr. Anca Pasca, Assistant Professor of Pediatrics, Neonatology at Stanford University

Title: Human Cellular Models for Hypoxic Brain Injury of Prematurity

Please register in advance here.


Tuesday, October 13th, 16-17 CET

  • Prof. Amalia Dolga, Associate Professor at University of Groningen

Title: Human stem cell models for targeting mitochondria and inflammation in neurodegeneration

  • Tessa de Vries, PhD Researcher, Erasmus University Medical Center

Title: Validation of vessel-on-chip model using cells from HTNB patients

Please register in advance here.


Associated dutch press media: Medicines

Medicines is an independent journal on drug research in the broadest sense of the word. Medicines provides news, backgrounds, interviews and opinions about the development of new medicines. This journal covers a variety of topics ranging from fundamental research to clinical studies, from policy to the shop floor, from opinions to hard facts, and from academy to start-ups and large pharmaceutical companies.
Medicines is published by for the Federation for Innovative Drug Research Netherlands (FIGON).

Our session “Regenerative pharmacology” was featured on the Medicine cover page. 

More information can be found on the website.